(Q45928691)

17 December 2017

title

Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. (English)

1 reference

17 December 2017

1 reference

Sun-Young Kong

1

1 reference

17 December 2017

Hyeong-Seok Lim

2

1 reference

17 December 2017

Byung-Ho Nam

3

1 reference

17 December 2017

Myeong-Cherl Kook

4

1 reference

17 December 2017

Young-Woo Kim

5

1 reference

17 December 2017

Keun Won Ryu

6

1 reference

17 December 2017

Jun Ho Lee

7

1 reference

17 December 2017

Il Ju Choi

8

1 reference

17 December 2017

Jin Soo Lee

9

1 reference

17 December 2017

Young-Iee Park

10

1 reference

17 December 2017

Noe Kyeong Kim

11

1 reference

17 December 2017

Sook Ryun Park

12

1 reference

17 December 2017

publication date

1 July 2009

1 reference

17 December 2017

published in

Pharmacogenomics

1 reference

17 December 2017

volume

10

1 reference

17 December 2017

issue

7

1 reference

17 December 2017

page(s)

1147-1155

1 reference

17 December 2017

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

cites work

1 reference

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

21 January 2018

1 reference

S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial

21 January 2018

1 reference

A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group

21 January 2018

1 reference

Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma

21 January 2018

1 reference

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

21 January 2018

1 reference

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer

21 January 2018

1 reference

Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.

21 January 2018

1 reference

Nicotine metabolism and CYP2A6 allele frequencies in Koreans

21 January 2018

1 reference

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

21 January 2018

1 reference

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

21 January 2018

1 reference

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

21 January 2018

1 reference

The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial

21 January 2018

1 reference

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

21 January 2018

1 reference

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function

21 January 2018

1 reference

Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.09.48

1 reference

17 December 2017

1 reference

17 December 2017